0001493152-21-015401.txt : 20210628 0001493152-21-015401.hdr.sgml : 20210628 20210628171552 ACCESSION NUMBER: 0001493152-21-015401 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20210628 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210628 DATE AS OF CHANGE: 20210628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 211054486 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 28, 2021

 

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35141   68-0370244
(Commission File Number)   (I.R.S. Employer Identification No.)

 

931 Village Boulevard, Suite 905, West Palm Beach,
Florida
  33409
(Address of Principal Executive Offices)   (Zip Code)

 

(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 

 

 

Item 8.01 Other Events

 

On June 28, 2021, Rennova Health, Inc. (the “Company”) issued a press release announcing the closing of its agreement with VisualMED Clinical Solutions Corp. (“VisualMED”) for VisualMED to acquire the Company’s software and genetic testing interpretation divisions. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Section 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Exhibit Description
     
Exhibit 99.1   Press Release dated June 28, 2021

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 28, 2021 RENNOVA HEALTH, INC.
     
  By: /s/ Seamus Lagan
    Seamus Lagan
    Chief Executive Officer
    (principal executive officer)

 

3

 

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

 

rennova IS pleased to report it has closed THE AGREEMENT TO SEPARATE ITS SOFTWARE AND GENETIC DIAGNOSTICS INTERPRETATION DIVISIONS into Visualmed clinical solutions corp. (OTC: VMCS)

 

WEST PALM BEACH, Fla. (June 28. 2021) – Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW) (“Rennova” or the “Company”), an owner and operator of rural hospitals in Tennessee, is please to confirm it has closed the agreement with VisualMED Clinical Solutions Corp. (VisualMED) a Nevada based public company, to merge its software and genetic testing interpretation divisions, Health Technology Solutions, Inc. (HTS) and Advanced Molecular Services Group, Inc., (AMSG) and their subsidiaries into VisualMED. These entities will operate as wholly owned subsidiaries of VisualMED which will immediately take the steps required to complete a name and trading symbol change.

 

VisualMED intends to complete the required filings to become compliant with SEC reporting requirements to become a fully reporting company as soon as practical.

 

Rennova and VisualMed intend to take the necessary steps to comply with the relevant regulations and rules to permit Rennova to distribute shares in VisualMED to its shareholders at some time in the future.

 

“We are delighted to have closed this transaction,” said Seamus Lagan, CEO of Rennova.

 

“Our software division has an exciting vision and plan to use our current solutions to create an innovative and we believe unique software solution for the health care industry. We remain convinced that vision can be better delivered and create more value for Rennova shareholders as a separate public entity.”

 

About Rennova Health, Inc.

 

Rennova owns and operates rural hospitals and a physician’s office in Tennessee and a physician’s office in Kentucky and provides industry-leading diagnostics and supportive software solutions to healthcare providers. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Contacts:

 

Rennova Health

Sebastien Sainsbury, 561-666-9818

ssainsbury@rennovahealth.com

 

# # #

 

 

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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